|Dr. Simon C. Pedder Ph.D.||Exec. Chairman||20.73k||N/A||1961|
|Mr. Joseph M. Miller CPA||CFO, Principal Exec. Officer, Principal Financial Officer & Sec.||388.23k||N/A||1974|
|Mr. James Archie Harrell Jr.||Chief Commercial Officer||433.91k||N/A||1970|
|Ms. Mariam E. Morris||Consultant||500.6k||N/A||1968|
|Dr. Solomon H. Snyder||Founder and Chairman of Scientific Advisory Board||N/A||N/A||1939|
Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-406 for the treatment of Parkinson's disease; CERC-425, an orally active small molecule; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and CERC-913, a protide nucleotide for the treatment of mitochondrial disorder. It also developing preclinical therapies CERC-801, CERC-802, and CERC-803 for the treatment of inherited metabolic disorders. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Cerecor Inc.’s ISS Governance QualityScore as of October 4, 2019 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 5; Compensation: 9.